Joshua Davis
Affiliations: | 2015- | Drug Discovery and Development | Auburn University, Auburn, AL, United States |
Google:
"Joshua Davis"Mean distance: (not calculated yet)
BETA: Related publications
See more...
Publications
|
You can help our author matching system! If you notice any publications incorrectly attributed to this author, please sign in and mark matches as correct or incorrect. |
| Mitra Ghosh T, Mazumder S, Davis J, et al. (2023) Metronomic Administration of Topotecan Alone and in Combination with Docetaxel Inhibits Epithelial-mesenchymal Transition in Aggressive Variant Prostate Cancers. Cancer Research Communications. 3: 1286-1311 |
| Davis JT, Ghosh TM, Mazumder S, et al. (2023) Extended Exposure Topotecan Significantly Improves Long-Term Drug Sensitivity by Decreasing Malignant Cell Heterogeneity and by Preventing Epithelial-Mesenchymal Transition. International Journal of Molecular Sciences. 24 |
| Habbit NL, Anbiah B, Anderson L, et al. (2022) Tunable three-dimensional engineered prostate cancer tissues for in vitro recapitulation of heterogeneous in vivo prostate tumor stiffness. Acta Biomaterialia |
| Mitra Ghosh T, Kansom T, Mazumder S, et al. (2021) . The Journal of Pharmacology and Experimental Therapeutics |
| Mitra Ghosh T, White J, Davis J, et al. (2021) Identification and Characterization of Key Differentially Expressed Genes Associated With Metronomic Dosing of Topotecan in Human Prostate Cancer. Frontiers in Pharmacology. 12: 736951 |
| Alnaim AS, Arnold R, Eggert M, et al. (2020) Role of PLA2R1 and sPLA2 on Drug Release and Uptake of Liposome Nanoparticles in Prostate Cancer The Faseb Journal. 34: 1-1 |
| Ghosh TM, Mitra AK, Davis J, et al. (2019) Abstract LB-267: Transcriptomic and epigenomic analysis of metastatic castration-resistant prostate cancer and a pan-cancer analysis of its genetic signatures Cancer Research |
| Davis J, Ghosh TM, Jasper L, et al. (2019) Abstract 32: Development of a three-dimensional spheroid model system to more accurately evaluate schedule dependent mechanistic differences between metronomic and conventional dosing of topotecan Cancer Research |
| Alnaim AS, Eggert MW, Nie B, et al. (2019) Abstract 2985: Identifying uptake and biodistribution of liposome nanoparticles associated with secretes phospholipase A2proteins and PLA2receptors within a prostate cancer Cancer Research |
| Ghosh TM, Davis J, Barnett GS, et al. (2019) Abstract 2944: Identification of key transcriptomic and epigenomic factors influencing conventional and metronomic dosing in aggressive and non-aggressive prostate cancer Cancer Research |